IP Library Granted Patent US 12673097
Granted Patent B2
US 12673097 · App. 18/028,613 · Granted Jul 7, 2026

DNA vaccine for SARS-COV-2

Inventors: Hironori Nakagami (Suita, JP); Ryuichi Morishita (Suita, JP); Hiroki Hayashi (Suita, JP); Yasunori Amaishi (Kusatsu, JP); Sachiko Okamoto (Kusatsu, JP); Junichi Mineno (Kusatsu, JP); Hisato Ikai (Ibaraki, JP); Junko Michibata (Ibaraki, JP); Takao Komatsuno (Ibaraki, JP)
Assignees: OSAKA UNIVERSITY; TAKARA BIO INC.; ANGES, INC.
A61K39/215A61P37/04A61K2039/53A61K2039/55505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673097
App. No.
18/028,613
Granted
Jul 7, 2026
Kind
B2
Abstract

Provided is DNA that: encodes a coronavirus (SARS COV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.

Claims (9)

1 . A DNA encoding a coronavirus SARS COV-2 spike protein or a fragment thereof, comprising a nucleotide sequence having 950% or more identity with a nucleotide sequence shown by SEQ ID NO: 3, 12, 14, 16 or 18.

2 . The DNA according to claim 1 , having a nucleotide sequence shown by SEQ ID NO: 3, 12, 14, 16 or 18.

3 . A nucleic acid construct containing a promoter that functions in a human and the DNA according to claim 1 operably linked to the promoter.

4 . The nucleic acid construct according to claim 3 , further containing a transcription termination sequence operably linked to the DNA.

5 . The nucleic acid construct according to claim 3 , which is incorporated into a vector.

6 . The nucleic acid construct according to claim 5 , which is incorporated into a vector selected from the group consisting of a plasmid vector, a phage vector and a viral vector.

7 . A pharmaceutical composition comprising the nucleic acid construct according to claim 3 .

8 . The pharmaceutical composition according to claim 7 , further comprising an adjuvant.

9 . The pharmaceutical composition according to claim 7 , which is a vaccine for coronavirus infection.